{
    "id": 9823,
    "fullName": "ROS1 M2128V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ROS1 M2128V lies within the protein kinase domain of the Ros1 protein (UniProt.org). M2128V has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of a Ros1 fusion in culture (PMID: 25351743), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6098,
        "geneSymbol": "ROS1",
        "terms": [
            "ROS1",
            "c-ros-1",
            "MCF3",
            "ROS"
        ]
    },
    "variant": "M2128V",
    "createDate": "07/30/2015",
    "updateDate": "02/21/2020",
    "referenceTranscriptCoordinates": {
        "id": 102388,
        "transcript": "NM_002944",
        "gDna": "chr6:g.117310133T>C",
        "cDna": "c.6382A>G",
        "protein": "p.M2128V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ROS1 E1990G and M2128V in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9818,
                "profileName": "CD74 - ROS1 ROS1 E1990G ROS1 M2128V"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CD74-ROS1 with ROS1 E1990G and M2128V were resistant to Zykadia (ceritinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9818,
                "profileName": "CD74 - ROS1 ROS1 E1990G ROS1 M2128V"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9818,
            "profileName": "CD74 - ROS1 ROS1 E1990G ROS1 M2128V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 9819,
            "profileName": "ROS1 M2128V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102388,
            "transcript": "NM_002944",
            "gDna": "chr6:g.117310133T>C",
            "cDna": "c.6382A>G",
            "protein": "p.M2128V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}